Tyra Biosciences (TYRA) Equity Ratio (2020 - 2026)

Tyra Biosciences has reported Equity Ratio for 7 years, with the latest figure at 0.94 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio changed 0.14% year-over-year to 0.94; the trailing twelve-month figure through Mar 2026 stood at 0.94 (changed 0.14% YoY), and the FY2025 full-year result was 0.92, down 2.84% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.94, up from 0.92 in the prior quarter.
• The five-year high for Equity Ratio was 0.98 in Q1 2023, with the low at 0.9 in Q4 2023.
• Historically, Equity Ratio has averaged 0.95 across 5 years, with a median of 0.95 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio dropped 6.63% — and 2024, when it increased 4.37%.
• Tyra Biosciences' Equity Ratio stood at 0.97 in 2022, then retreated by 6.63% to 0.9 in 2023, then advanced by 4.37% to 0.94 in 2024, then dropped by 2.84% to 0.92 in 2025, then grew by 2.57% to 0.94 in 2026.
• The last three Equity Ratio figures came in at 0.94 (Q1 2026), 0.92 (Q4 2025), and 0.93 (Q3 2025), per Business Quant data.